These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

444 related items for PubMed ID: 18674582

  • 1. Cost-effectiveness analysis of universal childhood vaccination against varicella in Brazil.
    Valentim J, Sartori AM, de Soárez PC, Amaku M, Azevedo RS, Novaes HM.
    Vaccine; 2008 Nov 18; 26(49):6281-91. PubMed ID: 18674582
    [Abstract] [Full Text] [Related]

  • 2. Varicella epidemiology and cost-effectiveness analysis of universal varicella vaccination program in Taiwan.
    Tseng HF, Tan HF, Chang CK.
    Southeast Asian J Trop Med Public Health; 2005 Nov 18; 36(6):1450-8. PubMed ID: 16610647
    [Abstract] [Full Text] [Related]

  • 3. An economic analysis of the universal varicella vaccination program in the United States.
    Zhou F, Ortega-Sanchez IR, Guris D, Shefer A, Lieu T, Seward JF.
    J Infect Dis; 2008 Mar 01; 197 Suppl 2():S156-64. PubMed ID: 18419391
    [Abstract] [Full Text] [Related]

  • 4. Economic burden of varicella in Singapore--a cost benefit estimate of implementation of a routine varicella vaccination.
    Jean-Jasmin LM, Lynette SP, Stefan M, Kai CS, Chew FT, Wah LB.
    Southeast Asian J Trop Med Public Health; 2004 Sep 01; 35(3):693-6. PubMed ID: 15689089
    [Abstract] [Full Text] [Related]

  • 5. Economic evaluation of varicella vaccination in Spain: results from a dynamic model.
    Lenne X, Diez Domingo J, Gil A, Ridao M, Lluch JA, Dervaux B.
    Vaccine; 2006 Nov 17; 24(47-48):6980-9. PubMed ID: 16860909
    [Abstract] [Full Text] [Related]

  • 6. Universal mass vaccination against varicella in Germany using an MMRV combination vaccine with a two-dose schedule: an economic analysis.
    Hammerschmidt T, Bisanz H, Wutzler P.
    Vaccine; 2007 Oct 16; 25(42):7307-12. PubMed ID: 17881097
    [Abstract] [Full Text] [Related]

  • 7. Can varicella be eliminated by vaccination? Potential clinical and economic effects of universal childhood varicella immunisation in Germany.
    Wutzler P, Neiss A, Banz K, Goertz A, Bisanz H.
    Med Microbiol Immunol; 2002 Oct 16; 191(2):89-96. PubMed ID: 12410347
    [Abstract] [Full Text] [Related]

  • 8. Economic evaluation of varicella vaccination in Italian children and adolescents according to different intervention strategies: the burden of uncomplicated hospitalised cases.
    Bonanni P, Boccalini S, Bechini A, Banz K.
    Vaccine; 2008 Oct 16; 26(44):5619-26. PubMed ID: 18723062
    [Abstract] [Full Text] [Related]

  • 9. Cost-effectiveness of varicella vaccination programs: an update of the literature.
    Rozenbaum MH, van Hoek AJ, Vegter S, Postma MJ.
    Expert Rev Vaccines; 2008 Aug 16; 7(6):753-82. PubMed ID: 18665775
    [Abstract] [Full Text] [Related]

  • 10. Cost-effectiveness of varicella vaccination of healthcare workers.
    Chodick G, Ashkenazi S, Livni G, Lerman Y.
    Vaccine; 2005 Oct 17; 23(43):5064-72. PubMed ID: 16046036
    [Abstract] [Full Text] [Related]

  • 11. An economic evaluation of varicella vaccination in Italian adolescents.
    Thiry N, Beutels P, Tancredi F, Romanò L, Zanetti A, Bonanni P, Gabutti G, Van Damme P.
    Vaccine; 2004 Sep 09; 22(27-28):3546-62. PubMed ID: 15315834
    [Abstract] [Full Text] [Related]

  • 12. Assessing the introduction of universal varicella vaccination in the Netherlands.
    Boot HJ, de Melker HE, Stolk EA, de Wit GA, Kimman TG.
    Vaccine; 2006 Sep 11; 24(37-39):6288-99. PubMed ID: 16790302
    [Abstract] [Full Text] [Related]

  • 13. [Impact of universal varicella vaccination in Germany: an epidemiological and economic analysis].
    Knuf M, Neiss A, Wutzler P.
    Klin Padiatr; 2006 Sep 11; 218(4):203-12. PubMed ID: 16819701
    [Abstract] [Full Text] [Related]

  • 14. The case against universal varicella vaccination.
    Goldman GS.
    Int J Toxicol; 2006 Sep 11; 25(5):313-7. PubMed ID: 16940003
    [Abstract] [Full Text] [Related]

  • 15. The economic value of childhood varicella vaccination in France and Germany.
    Coudeville L, Brunot A, Szucs TD, Dervaux B.
    Value Health; 2005 Sep 11; 8(3):209-22. PubMed ID: 15877593
    [Abstract] [Full Text] [Related]

  • 16. Economic evaluation of the 7-vaccine routine childhood immunization schedule in the United States, 2001.
    Zhou F, Santoli J, Messonnier ML, Yusuf HR, Shefer A, Chu SY, Rodewald L, Harpaz R.
    Arch Pediatr Adolesc Med; 2005 Dec 11; 159(12):1136-44. PubMed ID: 16330737
    [Abstract] [Full Text] [Related]

  • 17. Clinical and economic considerations of vaccination against varicella.
    Strassels SA, Sullivan SD.
    Pharmacotherapy; 1997 Dec 11; 17(1):133-9. PubMed ID: 9017774
    [Abstract] [Full Text] [Related]

  • 18. Cost-effectiveness analysis of a universal infant immunization program with meningococcal C conjugate vaccine in Brazil.
    de Soarez PC, Sartori AM, de Andrade Lagoa Nóbrega L, Itria A, Novaes HM.
    Value Health; 2011 Dec 11; 14(8):1019-27. PubMed ID: 22152170
    [Abstract] [Full Text] [Related]

  • 19. Cost-effectiveness and potential impact of rotavirus vaccination in the United States.
    Widdowson MA, Meltzer MI, Zhang X, Bresee JS, Parashar UD, Glass RI.
    Pediatrics; 2007 Apr 11; 119(4):684-97. PubMed ID: 17403839
    [Abstract] [Full Text] [Related]

  • 20. Economics of an adolescent meningococcal conjugate vaccination catch-up campaign in the United States.
    Ortega-Sanchez IR, Meltzer MI, Shepard C, Zell E, Messonnier ML, Bilukha O, Zhang X, Stephens DS, Messonnier NE, Active Bacterial Core Surveillance Team.
    Clin Infect Dis; 2008 Jan 01; 46(1):1-13. PubMed ID: 18171206
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.